Hepatocellular carcinoma (HCC) is one of the most common human cancers in the world, with an annual incidence of 250,000 cases. Epidemiological studies have shown an association of chronic infection of hepatitis B virus (HBV) with HCCs. Other risk factors include chronic infection of hepatitis C virus (HCV), heavy alcohol intake, and exposure to aflatoxin B1. However, the role of hepatotropic viral agents and the molecular events leading to liver carcinogenesis remain unknown. A mutagenic role of HBV DNA integration in the host genome, that occurs frequently in the early stages of HBV-associated tumorigenesis, has been conclusively established only in rare cases, 1, 2) suggesting the involvement of more indirect transformation pathways. A common feature in chronic viral hepatitis and liver cirrhosis is long lasting inflammation of the liver associated with chronic regenerative conditions, which might enhance the susceptibility of liver cells to genetic changes.
Inactivation of tumor-suppressor functions usually occurs as a consequence of mutation of one allele and loss of the other allele (loss of heterozygosity, LOH). 3, 4) In HCCs, LOH has been reported on chromosome arms 1p, 4q, 5q, 6q, 8p, 10q, 11p, 16p, 16q 17p, and 22q. [5] [6] [7] [8] [9] [10] In particular, we and others have previously noted frequent LOH involving loci on chromosome arm 10q in HCCs. [11] [12] [13] [14] [15] Analysis of homozygous deletions affecting chromosome 10q23 led to the identification of a new tumor suppressor gene in this region, designated PTEN/ MMAC1. 16, 17) Germline mutations of PTEN/MMAC1 are responsible for dominantly inherited neoplastic syndromes, Cowden disease and Bannayan-Zonona syndrome. 18, 19) PTEN/MMAC1 encodes a 403-amino acid dualspecificity phosphatase containing a region of homology to tensin and auxillin, cytoskeletal proteins that interact with adhesion molecules. 16, 17, 20) Somatic mutations of this gene have been detected in several tumor types including those of the uterus, brain, prostate, and the breast. 16, 17, [21] [22] [23] To determine the role of PTEN/MMAC1 genetic alterations in the development and/or progression of HCCs, we examined this gene for mutation and allelic loss in 96 primary HCCs, and looked for correlations between PTEN/MMAC1 mutations and certain clinicopathological parameters. Here we report evidence which suggests that both alleles of the PTEN/MMAC1 gene are inactivated in at least 5% of HCCs.
MATERIALS AND METHODS
Samples and DNA preparation Tumors and corresponding non-cancerous tissues were obtained from 96 patients who underwent surgery for primary HCCs. No metastases to other organs or distant lymph nodes were observed. All tissues were frozen immediately after surgery and stored at −80°C. DNA was extracted from frozen tissues by means of the procedures described previously. 24) The panel of clinico-pathological parameters studied included: tumor stage, serum hepatitis virus markers (HBsAg or HCVAb), histologic type, tumor size, and pathological state of surrounding non-tumorous liver. The tumor stage for each case was determined according to the TNM classification. Histological grades of HCC were divided into three categories (well-differentiated, moderately differentiated, and poorly differentiated carcinoma), according to the typing scheme of the Japanese Liver Cancer Society (1992). These three groups correspond to grade I, II, and III+IV, respectively, of the EdmondsonSteiner classification. LOH analysis Matched samples of normal and tumor genomic DNAs were analyzed for LOH with two microsatellite markers (D10S587 and D10S212) on the 10q arm near PTEN/MMAC1. Details of these markers were described in the CEPH/Genethon linkage map. 25) Each polymerase chain reaction (PCR) was performed in a Gene Amp PCR system 9600 (Perkin-Elmer Cetus, Norwalk, CT) using 10 ng of template DNA in 10 µl volumes of mixture containing 1× PCR buffer (Boehringer Mannheim, Tokyo), 200 mM each dNTPs, 2 pmol of unlabeled primer and 2 pmol of primer labelled with [γ-32 P]ATP, 10 ng of genomic DNA, and 0.25 U of Taq polymerase according to the procedures described previously. 26) Reaction was performed for 30 cycles under the following conditions; 94°C for 30 s, 55°C for 30 s, 72°C for 30 s. Ten microliters of loading buffer was added to each reaction, and each sample was denatured by boiling. A 3-µl aliquot of this solution was electrophoresed in 6% polyacrylamide gel containing 7.7 M formamide, for 4 h at 1800 V. Gels were dried and exposed to X-ray film for 24-48 h. Signal intensities of polymorphic alleles were quantified by a Hoefer GS-300 scanning densitometer (Hoefer Scientific Instruments, San Francisco, CA); peak areas corresponding to each signal were calculated by electronic integration using a GS-370 electrophoresis data system (Hoefer Scientific Instruments). The signal intensities of alleles of tumor-tissue DNAs were compared to those of corresponding normal-tissue DNAs. We judged a reduction in signal intensity >50% to be LOH.
Mutation analysis All tumor specimens were screened for mutations by PCR-single strand conformational polymorphism (SSCP) analysis following procedures described previously 27) for the entire PTEN/MMAC1 coding region, using PCR designed to amplify 27 overlapping segments according to the sequence registered in GenBank under the accession No. U93051 (Table I ). The lengths of the PCR products subjected to SSCP analysis ranged from 102 bp to 128 bp. Each segment was amplified in a volume of 10 µl containing 20 ng of genomic DNA, 1× PCR reaction buffer (Boehringer Mannheim), 200 mM dNTPs, 2 pmol each primer, 2 mCi of [α-32 P]dCTP, and 0.5 units of Taq polymerase. Cycling conditions were 30 cycles of 94°C for 30 s, 55-60°C for 30 s, and 72°C for 30 s, followed by a final extension at 72°C for 10 min (Gene Amp PCR 9600 System). Each PCR product was mixed with 10 µl of loading buffer (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanol), heated at 94°C for 5 min, rapidly cooled on ice, and applied to a 5% polyacrylamide gel containing 5% glycerol in 0.5× TBE buffer. Electrophoresis was performed under two different conditions to improve resolution for detecting different types of SSCP variants: 150 V for 16 h at room temperature, and 240 V for 16 h at 4°C. Gels were dried and autoradiographed with intensifying screens. For sequence analysis, DNA eluted from variant bands resolved on PCR-SSCP gel was excised and used as a template for PCR amplification under conditions described elsewhere. 27) Each of those PCR products was purified using SUPREC-02 (TaKaRa, Tokyo), according to the manufacturer's instructions. Sequencing was performed with a [γ-
32 P]-end-labeled primer using the ThermoSequenase cycle sequencing kit (Amersham, Cleveland, OH), according to the manufacturer's instructions. After electrophoresis at 1800 V for 2-3 h, gels were dried and exposed to X-ray film at room temperature for 16-24 h.
RESULTS

LOH analysis
Two microsatellite markers D10S587 and D10S212 on the 10q arm, around the PTEN/MMAC1 gene, were used for LOH analysis of 96 cases. Eightynine patients in our study were informative, and LOH at one or both of the marker loci was detected in 25 of the tumors (27%). PTEN/MMAC1 mutation PCR-SSCP screening of DNAs from the primary HCCs for mutations in the PTEN/MMAC1 gene itself detected aberrant bands in five cases; representative results are shown in Fig. 1 . These cases were subsequently analyzed by direct sequencing; Table II lists the somatic mutations identified among the tumors in our panel. All five mutations were present in tumor DNA, but not in corresponding normal DNA from the same patients. These mutations were not observed in 192 chromosomes derived from the general Japanese population. No significant association was observed between the mutations in the PTEN/MMAC1 gene and any clinicopathological parameter. Two-hit inactivation of the PTEN/MMAC1 gene We examined the allelic status of the five primary HCCs in which a subtle mutation was identified through the LOH analysis. In three of the four tumors informative for either marker, we were able to detect loss of an allele (tumors 43, 54 and 62; Table I ). These findings, together with the detection of mutation on one allele, suggest that two alleles of the PTEN/MMAC1 gene may be inactivated by a combination of intragenic point mutation on one allele and loss of chromosomal material on the other allele in most of these tumors.
DISCUSSION
The PTEN/MMAC1 gene, which lies at 10q23, has been identified as a predisposing gene for two dominantly inherited neoplastic syndromes. Germline mutations of PTEN/ MMAC1 were found in Cowden disease and BannayanZonana syndromes. Somatic mutations in PTEN/MMAC1 have been described in uterine, brain, prostate, and breast cancers. [16] [17] [18] [19] [20] [21] [22] [23] The present study represents the first extensive mutational screening of this gene in tumor DNA of primary HCCs. We identified five mutations in HCCs, all of which were somatic mutations.
The sensitivity of SSCP analysis that we utilized for mutation detection depends on the length and the primary structure of the fragment to be analyzed and on the conditions chosen for electrophoresis. Although we designed PCR primers so that each amplicon falls within a short fragment size range (102-128 bp) to achieve higher sensitivity, it is known that certain DNA variations are undetectable by SSCP under some electrophoretic conditions. Thus, though we carried out our electrophoretic experiments under two different sets of conditions, some subtle mutations might have escaped detection by our SSCP method. The apparent discrepancy between the rate of LOH on 10q23 and the rate of subtle mutation within the PTEN/MMAC1 gene may be partly explained by such incompleteness of detection. We screened the complete coding sequence of the PTEN/MMAC1 gene by SSCP, but not the upstream promoter regions, introns, and the 3′ noncoding regions. Any subtle mutations present in those regions would have escaped our SSCP screening, and this may also partly explain the apparent discrepancy between the rates. In previous reports that analyzed brain, prostate, breast and endometrial tumors, as well as inherited neoplastic syndromes, the majority of PTEN/MMAC1 mutations were also detected in exons 5, 7 and 8. [16] [17] [18] [19] [20] [21] [22] [23] Of those, most of the missense mutations were identified in exon 5, encoding the putative phosphatase domain, and exons 7 and 8, encoding a potential tyrosine kinase phosphorylation site, which are essential for the function of the PTEN/ MMAC1 protein. In the present study of primary HCCs, mutations were detected in three of the nine exons; exons 1, 4 and 8. In addition, in our series of HCCs, no missense mutation was detected in the PTEN/MMAC1 gene, whereas a somatic mutation at −9 in the 5′ non-coding region was identified in two tumors. Although the functional significance of this mutation, whether transcriptional or post-transcriptional, remains to be elucidated, the specificity in mutation pattern may be a characteristic feature of PTEN/MMAC1 mutation in HCCs.
Our study revealed LOH in 25 (27%) of the 89 informative tumors. In the majority of the tumors in which we identified point mutations of the PTEN/MMAC1 gene, we detected allelic loss with markers surrounding the PTEN/ MMAC1 locus. PTEN/MMAC1 encodes a 403-amino acid dual-specificity phosphatase containing a region of homology to tensin and auxillin, cytoskeletal proteins that interact with adhesion molecules. Thus, deletion of this locus might profoundly alter the growth of hepatocytes. Germline mutations of PTEN/MMAC1 gene are responsible for Cowden disease and Bannayan-Zonona syndrome, in which elevated risk of breast and thyroid cancers is noted in the affected family members. Cowden disease is not associated with elevated risk of hepatocellular carcinoma. However, results presented here indicate that somatic PTEN/MMAC1 mutations are present in a portion of hepatocellular carcinomas. We suggest that the PTEN/ MMAC1 gene is altered in a portion of hepatocellular carcinomas and that inactivation of this gene occurs during the course of hepatocellular carcinogenesis.
